Because pCR was the primary end point of our study, we will focus on the following issues: (1) whether adding bevacizumab would increase pCR, (2) whether such an increase or decrease would be statistically significant, (3) which subgroup would benefit the most according to HER2 status, and (4) which subgroup of patients with HER2-negative cancer would benefit the most according to HR status. This evidence concerns the gene ERBB2 and cancer.